Bicara presents survival data for ficerafusp alfa + Keytruda in head/neck cancer: 21.3 months median OS, 46% 2-year OS rate ...

Checkpoint therapies like Keytruda, Opdivo, and Imfinzi are expanding from late-stage to early-stage cancer treatment, with ...

Takeda and Protagonist Therapeutics are on the comeback trail with rusfertide, almost four years after the rare blood disease ...

AstraZeneca/Daiichi's Enhertu shows survival benefit vs standard care in HER2+ gastric cancer patients, with 14.7 vs 11.4 ...

Arvinas' vepdegestrant shows 43% reduced risk of progression or death in ESR1-mutated breast cancer patients vs hormone ...

Appeals court denies HHS request to pause lower court order blocking federal agency restructuring plans that would cut 10,000 ...

Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: ...

AstraZeneca and Handa Pharmaceuticals have agreed to pay a combined $51.4 million to resolve a class action lawsuit that ...

Summit Therapeutics' ivonescimab shows 48% PFS benefit but misses OS endpoint in Phase 3 lung cancer trial; drug's regulatory ...

Biopharma faces uncertainty in H2 2025 amid policy concerns and market challenges, with key healthcare conferences and ...

Adding Pfizer’s BRAF inhibitor Braftovi to a cocktail of cancer drugs cut the risk of death for certain colorectal cancer ...

Astellas is the latest large pharmaceutical company to ink a deal with a Chinese biotech, paying $130 million upfront for a ...